Gene expression patterns for GDNF and its receptors in the human putamen affected by Parkinson's disease: a real-time PCR study - PubMed (original) (raw)
. 2006 Jun 27;252(1-2):160-6.
doi: 10.1016/j.mce.2006.03.013. Epub 2006 Apr 27.
Affiliations
- PMID: 16644101
- DOI: 10.1016/j.mce.2006.03.013
Gene expression patterns for GDNF and its receptors in the human putamen affected by Parkinson's disease: a real-time PCR study
Cristina M Bäckman et al. Mol Cell Endocrinol. 2006.
Abstract
Glial cell line-derived neurotrophic factor (GDNF), a member of the transforming growth factor-beta superfamily, is a potent trophic factor for dopaminergic neurons of the ventral midbrain, which are known to degenerate during Parkinson's disease (PD). The neuroprotective, neurorestorative, and stimulatory properties of GDNF has prompted numerous suggestions that this trophic factor may be a potential therapeutic tool to treat PD, and it has also been widely speculated that altered GDNF expression levels may be involved in the pathophysiology of the disease. In this study, we have investigated if mRNA expression levels for GDNF and/or its receptors are altered during PD in the human putamen, a target area for dopamine neurons of the substantia nigra compacta. Expression levels were analyzed with quantitative real-time reverse transcriptase polymerase reaction (RT qPCR) in post-mortem tissues from PD patients and aged matched controls. Primer pairs specific for GDNF (isoforms I and II), and its receptor molecules, GFRalpha1 and cRET were utilized. GDNF, cRET and GFRalpha1 mRNA expression was clearly detected in the putamen of control and Parkinson's disease patients. A modest but significant upregulation of GDNF mRNA levels (Isoform I) was observed in the putamen of Parkinson's disease patients with a marked loss of nigral neurons. No significant changes were observed for the expression of cRet and GFRa1. These data suggest that the extensive loss of dopaminergic neurons in the substantia nigra, and concomitant loss of striatal dopamine, may induce compensatory changes in the expression of target derived GDNF, but not its receptor system.
Similar articles
- Striatal expression of GDNF and differential vulnerability of midbrain dopaminergic cells.
Barroso-Chinea P, Cruz-Muros I, Aymerich MS, Rodríguez-Díaz M, Afonso-Oramas D, Lanciego JL, González-Hernández T. Barroso-Chinea P, et al. Eur J Neurosci. 2005 Apr;21(7):1815-27. doi: 10.1111/j.1460-9568.2005.04024.x. Eur J Neurosci. 2005. PMID: 15869477 - 6-Hydroxydopamine induces distinct alterations in GDF5 and GDNF mRNA expression in the rat nigrostriatal system in vivo.
Gavin AM, Walsh S, Wyatt S, O'Keeffe GW, Sullivan AM. Gavin AM, et al. Neurosci Lett. 2014 Feb 21;561:176-81. doi: 10.1016/j.neulet.2013.12.046. Epub 2013 Dec 25. Neurosci Lett. 2014. PMID: 24373993 - Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease.
Grondin R, Gash DM. Grondin R, et al. J Neurol. 1998 Nov;245(11 Suppl 3):P35-42. doi: 10.1007/pl00007744. J Neurol. 1998. PMID: 9808338 Review. - Potential Therapeutic Approach using Aromatic l-amino Acid Decarboxylase and Glial-derived Neurotrophic Factor Therapy Targeting Putamen in Parkinson's Disease.
Tripathi RK, Goyal L, Singh S. Tripathi RK, et al. Curr Gene Ther. 2024;24(4):278-291. doi: 10.2174/0115665232283842240102073002. Curr Gene Ther. 2024. PMID: 38310455 Review.
Cited by
- Endophenotypes as a measure of suicidality.
Chistiakov DA, Kekelidze ZI, Chekhonin VP. Chistiakov DA, et al. J Appl Genet. 2012 Nov;53(4):389-413. doi: 10.1007/s13353-012-0113-1. Epub 2012 Sep 2. J Appl Genet. 2012. PMID: 22941515 Review. - Effects of naringin, a flavanone glycoside in grapefruits and citrus fruits, on the nigrostriatal dopaminergic projection in the adult brain.
Jung UJ, Kim SR. Jung UJ, et al. Neural Regen Res. 2014 Aug 15;9(16):1514-7. doi: 10.4103/1673-5374.139476. Neural Regen Res. 2014. PMID: 25317167 Free PMC article. Review. - Is activation of GDNF/RET signaling the answer for successful treatment of Parkinson's disease? A discussion of data from the culture dish to the clinic.
Conway JA, Kramer ER. Conway JA, et al. Neural Regen Res. 2022 Jul;17(7):1462-1467. doi: 10.4103/1673-5374.327330. Neural Regen Res. 2022. PMID: 34916419 Free PMC article. Review. - Enhanced dopamine transporter activity in middle-aged Gdnf heterozygous mice.
Littrell OM, Pomerleau F, Huettl P, Surgener S, McGinty JF, Middaugh LD, Granholm AC, Gerhardt GA, Boger HA. Littrell OM, et al. Neurobiol Aging. 2012 Feb;33(2):427.e1-14. doi: 10.1016/j.neurobiolaging.2010.10.013. Epub 2010 Dec 8. Neurobiol Aging. 2012. PMID: 21144620 Free PMC article. - Adeno-Associated Viral Vectors as Versatile Tools for Parkinson's Research, Both for Disease Modeling Purposes and for Therapeutic Uses.
Fajardo-Serrano A, Rico AJ, Roda E, Honrubia A, Arrieta S, Ariznabarreta G, Chocarro J, Lorenzo-Ramos E, Pejenaute A, Vázquez A, Lanciego JL. Fajardo-Serrano A, et al. Int J Mol Sci. 2021 Jun 15;22(12):6389. doi: 10.3390/ijms22126389. Int J Mol Sci. 2021. PMID: 34203739 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical